EDITORIAL SECTIONS
RESEARCH & DEVELOPMENT
Adopting the Power of AI to Drug Development Projects
A tremendous amount of documentation is created throughout the clinical trial lifecycle
CLINICAL TRIALS
Real-world Evidence
Hearing the diagnosis from the doctor that your child has spinal muscular atrophy SMA
MANUFACTURING
Just in Time Manufacturing Creating more sustainable supply chains
Drug development has transformed immeasurably over the past decade Even before the Covid pandemic and the conflict in Ukraine
Information Technology
Challenges and Advantages of Using Artificial Intelligence in Pharma
Many advanced largescale AI initiatives still need to be proved successful in Pharma
KNOWLEDGE BANK
Interviews
Why Do Pharma Construction Projects Need Cost Certainty | Linesight | ISPE Singapore 2026 | Pharma Focus Asia
Associate Director, Project Controls, Linesight
Stephanie Ledwidge is an experienced project controls and cost management professional with expertise across the life sciences and pharmaceutical sectors She currently serves as Associate Director Project Controls at Linesight in Singapore Her experience spans project controls cost engineering project coordination and project delivery with previous roles supporting organisations including CSL Behr...
Articles
Novel Claudin Targeted C-terminal Clostridium Perfringens Enterotoxin Conjugated Anticancer Nanotherapeutics
Active targeting with nanomedicines can result in effective drug delivery to targeted cells maximising therapeutic efficacy while decreasing systemic side effects The main application of this approach is paying attention toward cancer therapy Cancer threats were found in worldwide population due to increasing adoption of cancercausing behaviors
Research Insights
Optimizing the Dose of Pre-Pandemic Influenza Vaccines to Reduce the Infection Attack Rate
Steven Riley Joseph T Wu Gabriel M Leung Background The recent spread of avian influenza in wild birds and poultry may be a precursor to the emergence of a like human pandemic Therefore stockpiles of human prepandemic vaccine targeted at avian strains are being consider
Case Studies
Applying Data Mining Techniques To Medical Time Series: An Empirical Case Study
Abstract One of the major challenges in the medical domain today is how to exploit the huge amount of data that this field generates To do this approaches are required that are capable of discovering knowledge that is useful for decision making in the medical field Time series are data types that are common in the medical domain and require specialized analy
Techno Trends
AstraZeneca and Roche Announce Strategic Partnership to Advance Oncology Research in Asia
The collaboration aims to enhance oncology research and drug development across Asia
White Papers
Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches
In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS
TOP ARTICLES
The Value in Decolonising Drug Discovery
Jesse Grey Eagle (Oglala Lakota) is the founder of Indigenous Futures OS and a governance designer for Tribal nations. He works at the nexus of ethical data, AI sovereignty, and long-view institutional systems, advocating for partnership architectures that move beyond extraction.
Sabah Ul-Hasan is a Ph.D. scientist with over 15 years of practice in the life sciences. An Indian-Pakistani American based in Albuquerque (New Mexico), Dr. Ul-Hasan centers on ethical data practices that bridge science with community-based knowledge systems.
Integrated by Design
Venkat Reddy Sunkara is global head of Regulatory CMC at ICON. He has extensive expertise in managing Chemistry, Manufacturing, and Controls (CMC) aspects of regulatory submissions and post market compliance, supporting clients in achieving and maintaining adherence to global regulatory requirements. He brings over 20 years of pharmaceutical industry experience, including more than 10 years in CMO/CRO environments specializing in Regulatory CMC.
Multi-Target Directed Ligands and Lipidomics Approach for Glioblastoma Drug Discovery
Dr. Stevan Pecic is an assistant professor at the Department of Chemistry and Biochemistry at California State University, Fullerton. His main research interests and assignments are focused on the identification of novel inhibitors of enzymes involved in lipid metabolism and their evaluation as potential therapeutics in pain management.
Xiaohui Weng earned a bachelor’s in chemistry from Fordham University and recently completed her master’s degree working in Dr. Pecic medicinal chemistry lab at California State University, Fullerton. Her current research focuses on target identification for glioblastoma and the synthesis of new anti-cancer drugs.
Michael Gonzalez is a graduate student pursuing a master’s in chemistry at California State University Fullerton. Currently he also interns at a start-up biotech company, playing an important role in chemistry development for their high-throughput macrocyclic synthesis platform.
Arya obtained his Hon. BSc. in Human kinetics from University of Guelph, where he completed a summer internship at Dr. Ghavami’s lab at University of Manitoba. Arya then pursued a double major from York University majoring in Neuropsychology. Arya’s research under the supervision of Dr. Ghavami resulted in four publications, and he has since been involved in the review and publication process of manuscripts in highly regarded journals. Arya is currently entering the second year of his Doctor of Dental Surgery program at the Faculty of Dentistry, University of Toronto.
Dr. Amir Barzegar Behrooz is a cancer researcher and postdoctoral fellow at the College of Pharmacy, University of Manitoba. His work focuses on various aspects of cancer biology, particularly glioblastoma. His work focuses on targeted cancer therapy, and theranostic targets in cancer cells via Onco-Multi-OMICS.
Dr. Rui Vitorino, Principal Investigator at the University of Aveiro, specializes in OMICS, proteomics, and bioinformatics. His research on biofluids like saliva and urine aims to uncover disease pathways and biomarkers. Vitorino's multidisciplinary approach enhances early disease detection, influencing molecular and cell biology studies significantly.
Dr. Ghavami, an Associate Professor at the University of Manitoba, specializes in apoptosis, autophagy, and unfolded protein response regulation. With over 300 publications and numerous awards, he's globally recognised. Affiliated with institutions worldwide, he serves as Associate Editor for multiple scientific journals.
Kinase Inhibitors as Antiviral Agents
Thanigaimalai Pillaiyar is working as an independent junior research group leader and establishing a research group at the Tübingen Center for Academic Drug Discovery (TüCAD2), University of Tübingen. His research interests include medicinal chemistry of orphan G protein-coupled receptors (GPCRs), synthetic organic chemistry, and dual SARS-CoV-2 Mpro-kinase inhibitors.
Stefan Laufer is Professor for Pharmaceutical/Medicinal Chemistry at Tuebingen University and chairs the TüCAD2. His research interests are anti inflammatory and cancer drug discovery. He authored more than 500 publications, 15 books/book chapters and is inventor in 42 patent families with >330 national applications. 4 compounds from his lab made it to first into man studies.
Pharma Regulatory Bottlenecks and Vaccination Delays
Sonam Chandwani is the Managing Partner at KS Legal & Associates. Her experience encompasses commercial and crosses border transactions across various sectors, advising both Indian companies in their outbound investments and foreign companies investing in India, on diverse areas of Indian laws concerning Mergers & Acquisitions, Insolvency & Bankruptcy, Banking & Finance, Real Estate, Arbitration and Litigation in Courts and Tribunals on a PAN-India basis.
press releasesRead more...
HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Autoimmune Hemolytic Anemia
HUTCHMED China Limited announces that the US Food and Drug Administration FDA has granted Orphan Drug Designation to sovleplenib for the treatment of autoimmune hemolytic anemia AIHA Sovleplenib is a novel selective oral spleen tyrosine kinase Syk inhibitor
Abbott and Novo expand partnership to launch Plosbrio® broadening access to semaglutide for advanced diabetes care across Asia Pacific
Abbott the global healthcare leader and Novo a global leader in treatments for serious chronic diseases announced an expanded strategic collaboration to increase access to originator semaglutide for people living with type diabetes across Asia Pacific Under the agreement Abbott will commercialise
Zuellig Pharma Strengthens Clinical Sourcing Capabilities in China through Strategic Acquisition
Zuellig Pharma a leading healthcare solutions company in Asia announced the strategic acquisition of a specialized clinical supply facility in Hangzhou China strengthening its clinical sourcing capabilities to better support domestic and international clinical trials
Teva and Samsung Bioepis Announce Agreement to Commercialize Two FDA-Approved Biosimilars in the U.S.
Teva Pharmaceutical Industries Ltd and Samsung Bioepis Co Ltd today announced that they have entered into a license and commercialization agreement for two FDAapproved immunology biosimilars infliximababda a biosimilar to Remicade infliximab and ETICOVO etanerceptykro a biosimilar to Enbrel etanerc...
USP statement on quality and safety considerations for unapproved peptides
USP is concerned about the potential harm to patients from unapproved peptide products However the Department of Health and Human Services HHS Enforcement Discretion Policy released last week regarding the compounding of certain peptide bulk drug substances under A of the Federal Food Drug and Cosme...
Illumina selected to help bring precision medicine into everyday healthcare in Singapore
Illumina Inc today announced it has been selected to provide wholegenome sequencing services for the SGINSIGHT study a cohort under Phase III of Singapores National Precision Medicine NPM programme Expected to include approximately one in Singapore residents or around individuals
EventsRead more...
03 - 05
Nov 202610th Dermatology Drug Development
Boston, Massachusetts at The C...
04 - 05
Nov 2026Advanced Therapies USA
Hynes Convention Center, Bosto...
05 - 05
Nov 2026PDA Contamination Control Strategy Workshop
Sheraton Grand Incheon Hotel,...
09 - 11
Nov 202611th Microbiome Movement USA Summit
The Colonnade Hotel, Boston, M...
10 - 11
Nov 2026Extractables & Leachables Europe
Parkhotel Schӧnbrunn, Vienna,...
11 - 13
Nov 2026Frontiers in Cancer Science 2026
One Farrer Hotel,1 Farrer Park...
11 - 12
Nov 2026Medical Device Project and Portfolio Management
Chicago, IL, USA
16 - 17
Nov 2026Analytics for Smarter Decisions in Pharma
London, UK
LATEST NEWSRead more...
Boehringer Ingelheim Enters into Partnership with SBP Group to Advance Next-Generation Cancer Therapies
Boehringer Ingelheim and Sino Biopharmaceutical SBP Group have entered into a multiprogram partnership to develop potential nextgeneration cancer treatments using antibodydrug conjugate ADC and Tcell engager TcE technologies
MindWalk Partners with Teva to Support Antibody Discovery Using AI
MindWalk has entered into a multiyear agreement with Teva Pharmaceuticals Australia to support antibody discovery and design optimisation using AI technology ReefIQ is MindWalks biological context platform for the life sciences sector powered by its HYFT technology The technology
CStone Enters into Collaboration with Kimia Therapeutics to Advance Clinical Development of Novel Oncology Drug
CStone Pharmaceuticals has entered into a clinical development collaboration with USbased Kimia Therapeutics to advance a potential firstinclass drug candidate targeting the DNA damage response DDR pathway which plays an important role in the survival of solid tumour cells
DKSH and The Baker Company Partner to Expand Cell Culture and Microbiology Research
DKSH Business Unit Technology has entered into an exclusive distribution agreement with The Baker Company to make its Baker Ruskinn range of controlledenvironment technologies available to laboratories across Thailand The partnership aims to improve access to equipment used in cell culture tissue c...
Fresenius Enters into Agreement with WuXi Biologics to Expand Biosimilars Pipeline
Fresenius has entered into an exclusive development agreement with WuXi Biologics to expand its biosimilars pipeline and strengthen its biopharmaceutical business The partnership will give Fresenius access to WuXi Biologics capabilities in biologics research development and manufacturing
Edison Scientific Enters into Agreement with Pfizer to Advance Drug Research and Development
Edison Scientific has entered into an agreement with Pfizer to introduce its Edison AI Platform and AI scientist Kosmos across Pfizers biopharmaceutical research and development activities The collaboration will combine Edison Scientifics artificial intelligence AI technology with Pfizers scientific...
